[1] Gai XD,Wu WF.Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis.Exp Ther Med,2017,14: 3908-3914.
[2] 黄雪,刘传苗,赵守松,等. 失代偿期肝硬化患者SAAG、PA、PTA水平与肝功能分期及预后的关系. 世界华人消化杂志,2016,24:790-795.
[3] 谭建荣,罗显克,王大东,等. 肝硬化患者血清胆碱酯酶和腺苷脱氨酶联合检测的临床意义. 现代生物医学进展,2014,14:1494-1496.
[4] Davies T,Wythe S,O'Beirne J,et al.Review article: the role of the microcirculation in liver cirrhosis.Aliment Pharmacol Ther,2017,46:825-835.
[5] Ramachandran J,Sajith KG,Priya S,et al.Serum cholinesterase is an excellent biomarker of liver cirrhosis.Trop Gastroenterol,2014,35:15-20.
[6] 季晓军,王伟军. 乳果糖对乙肝后肝硬化患者肝功能、炎症及肠道通透性水平的影响. 实用药物与临床,2014,17:1158-1161.
[7] 来丽群,樊德利. 乙肝后肝硬化不同中医证型与TGF-β1肝纤维化指标以及肝功能分级的相关性的研究. 中国卫生检验杂志,2014,24:808-811.
[8] Chen Y,Yang S,Peng Y,et al.The regulatory role of IL-6R in hepatitis B-associated fibrosis and cirrhosis.Braz J Med Biol Res,2017,50:e6246. |
